Drug intelligence / Profile preview

ketanserin

Development stage
Phase 4
Lead developer
Janssen Pharmaceutica
Modality
Small Molecules
Administration
Oral, Intravenous, Topical
01

Overview

Ketanserin is an antihypertensive agent primarily used to treat arterial hypertension and vasospastic disorders. It acts as a high-affinity, non-selective antagonist of serotonin 5-HT2 receptors (notably 5-HT2A) and also exhibits antagonistic activity at histamine H1 receptors and weak alpha 1-adrenoceptor blocking properties. Ketanserin inhibits serotonin-induced vasoconstriction, platelet activation, and aggregation, leading to reduced systemic vascular resistance and improved vascular compliance. It has been shown to lower blood pressure—especially in older adults—and improve microcirculation in conditions such as Raynaud's disease and scleroderma-related ulcers. Ketanserin is also used in scientific research for its antiserotonergic effects on the serotonin system[1][3][4][5][8].

Brand names
Sufrexal
Other names
ketanserina
02

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on ketanserin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketanserin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call